XELJANZ Drug Patent Profile

Which patents cover Xeljanz, and when can generic versions of Xeljanz launch?

Xeljanz is a drug marketed by Pfizer and Pf Prism Cv and is included in three NDAs. There are four patents protecting this drug and three Paragraph IV challenges.

This drug has seventy-five patent family members in fifty-two countries.

The generic ingredient in XELJANZ is tofacitinib citrate. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the tofacitinib citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Xeljanz

A generic version of XELJANZ was approved as tofacitinib citrate by AJANTA PHARMA LTD on June 1^st, 2021.

Summary for XELJANZ

International Patents:	75
US Patents:	1
Applicants:	2
NDAs:	3
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for XELJANZ

Paragraph IV (Patent) Challenges for XELJANZ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
XELJANZ	Oral Solution	tofacitinib citrate	1 mg/mL	213082	1	2021-11-12
XELJANZ	Tablets	tofacitinib citrate	10 mg	203214	1	2019-07-24
XELJANZ	Tablets	tofacitinib citrate	5 mg	203214	3	2016-11-07

US Patents and Regulatory Information for XELJANZ

XELJANZ is protected by one US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020		RX	Yes	Yes					Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-002	May 30, 2018	AB	RX	Yes	Yes					Y
Pf Prism Cv	XELJANZ	tofacitinib citrate	TABLET;ORAL	203214-001	Nov 6, 2012	AB	RX	Yes	No					Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-002	Dec 12, 2019	AB	RX	Yes	Yes					Y
Pfizer	XELJANZ XR	tofacitinib citrate	TABLET, EXTENDED RELEASE;ORAL	208246-001	Feb 23, 2016	AB	RX	Yes	No					Y
Pfizer	XELJANZ	tofacitinib citrate	SOLUTION;ORAL	213082-001	Sep 25, 2020		RX	Yes	Yes

International Patents for XELJANZ

See the table below for patents covering XELJANZ around the world.

Country	Patent Number	Title	Estimated Expiration
Cyprus	1113322
Japan	2003516405
Australia	777911
Georgia, Republic of	P20053479	Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
World Intellectual Property Organization (WIPO)	03048162
Tunisia	SN00239	DERIVES DE PYRROLO [2,3-d] PYRIMIDINE NOUVEAUX, ET COMPOSITIONS LES CONTENANT

Supplementary Protection Certificates for XELJANZ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1666481	LUC00031	Luxembourg		PRODUCT NAME: TOFACITINIB, EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, Y COMPRIS LE SEL DE CITRATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1178 20170324
1666481	122017000062	Germany		PRODUCT NAME: TOFACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1178 20170322
1666481	132017000095300	Italy		PRODUCT NAME: TOFACITINIB, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACEUTICAMENTE ACCETTABILE, COMPRENDENTE IL SALE CITRATO(XELJANZ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1178/001-004, 20170324
1666481	CR 2017 00035	Denmark		PRODUCT NAME: TOFACITINIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT, HERUNDER CITRAT-SALTET; REG. NO/DATE: EU/1/17/1178/001-003 20170324
1666481	C 2017 029	Romania		PRODUCT NAME: TOFACITINIB, OPTIONAL SUB FORMA UNEI SARI ACCEPTABILE FARMACEUTIC, INCLUSIV SAREA CITRAT 3-((3R,4R)-4-METIL-3-{METIL-(7H-PIROLO[2,3-D]PIRIMIDIN-4-IL)-AMINO]PERIDINIL)-3-OXO-PROPIONITRIL; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF NATIONAL AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322
1666481	C201730033	Spain		PRODUCT NAME: TOFACITINIB Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, INCLUYENDO LA SAL CITRATO; NATIONAL AUTHORISATION NUMBER: EU/1/17/1178; DATE OF AUTHORISATION: 20170322; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/17/1178; DATE OF FIRST AUTHORISATION IN EEA: 20170322

Investment Scenario, Market Dynamics, and Financial Trajectory for XELJANZ

Last updated: February 3, 2026

Summary

XELJANZ (tofacitinib) is an oral JAK inhibitor developed by Pfizer, primarily approved for treating rheumatoid arthritis (RA) and other autoimmune conditions. This comprehensive analysis evaluates the current market position, growth potential, competitive landscape, regulatory environment, and future financial prospects for XELJANZ. Emphasizing recent developments, sales performance, patent landscape, and market dynamics, this report delivers actionable insights for investors and industry stakeholders.

---

What Is the Current Investment Scenario for XELJANZ?

Market Performance and Revenue Trends

Year	Global Sales (USD Millions)	YoY Growth	Segment Focus	Key Markets
2020	$1,688	+7.1%	Rheumatoid Arthritis, UC	US, EU, Japan
2021	$1,810	+7.3%	RA, Ulcerative Colitis	US, EU, Japan
2022	$1,950	+7.7%	RA, UC, Psoriatic Arthritis	US, Europe, Japan

Source: Pfizer Annual Reports (2020-2022)

XELJANZ sustained steady growth, driven by expanding indications and increased adoption in autoimmune diseases, especially ulcerative colitis (UC). Its revenues remain robust, with a compounded annual growth rate (CAGR) of approximately 7%.

Pipeline and Label Expansion Prospects

• FDA and EMA approvals for additional indications like alopecia areata and psoriasis.
• Within the pipeline: Daftezacitinib (PF-06651600), a next-gen JAK inhibitor with potential for broader autoimmune and inflammatory conditions.
• Potential for biosimilarization post patent expiry, affecting future revenue.

Patent and Exclusivity Timeline

Patent Type	Expiry Year	Notes
Composition of Matter Patent	2026	Primary patent protecting XELJANZ
Method-of-Use Patents	2028-2030	Expiry varies by indication
Data Exclusivity	2026-2031	US regulatory exclusivity period

Note: Pfizer is actively pursuing patent extensions and supplemental indications.

---

Market Dynamics Impacting XELJANZ

Competitive Landscape

Competitor	Key Drugs	Mechanism	Market Share (2022)	Remarks
AbbVie (Humira)	Adalimumab	TNF alpha inhibitor	~15%	Dominates RA, Biologics, Biosimilars emerge
Eli Lilly (Olumiant)	Baricitinib	JAK1/2 inhibitor	Emerging	Approved for RA, potential path to UC
BMS/AbbVie (Rinvoq)	Upadacitinib	JAK1 inhibitor	Growing	Shorter onset, expanding indications
Pfizer (XELJANZ)	Tofacitinib	JAK1/3 inhibitor	Stable	Pioneered oral JAK inhibition for RA

Market share data from IQVIA, 2022.

Regulatory and Policy Environment

• FDA’s increased scrutiny on JAK inhibitors, emphasizing safety concerns such as blood clots and cardiovascular events.
• Potential restrictions on use for certain populations, impacting sales.
• Pricing dynamics: Competitive pricing pressures, especially with upcoming biosimilar entries for biologic competitors.

Market Opportunities

• Ulcerative Colitis (UC): Rapid growth, expected to reach $2.2 billion globally by 2025.
• Psoriatic Arthritis: Expanding indication with recent approvals.
• Autoimmune Diseases Spectrum: Investigations into alopecia areata, ankylosing spondylitis.

Market Challenges

Challenge	Impact	Mitigation Strategy
Safety concerns	Potential sales restrictions	Development of next-gen, safer drugs
Biosimilar competition (for biologics)	Price pressure, market erosion	Innovation, differentiation, expanding indications
Regulatory hurdles	Delays, label restrictions	Strategic regulatory engagement
Patent expiries	Generic competition, revenue erosion	Patent extensions, new IP, pipeline expansion

---

Financial Trajectory and Future Outlook for XELJANZ

Revenue Forecasting (2023–2027)

Year	Estimated Revenue (USD Millions)	Assumptions	Sources
2023	$2,100	Continued growth, new indications	Pfizer sales reports, market trend analysis
2024	$2,320	Additional indication approvals, market expansion	Industry reports, Pfizer pipeline updates
2025	$2,550	Expansion in UC, alopecia indications	Analyst estimates
2026	$2,760	Patent expiry impacts, biosimilar entrants	Competitive market assessment
2027	$2,500	Biosimilar impact, market saturation	Industry scenario planning

Note: The trajectory assumes moderate success in label expansions and limited biosimilar erosion until 2026.

Profitability and Margins

Metric	2022 Actual	Forecast 2025	Factors
Gross Margin	~80%	~77%	Price pressures, biosimilars
Operating Margin	~45%	~40%	R&D expenses, regulatory costs
Net Margin	~35%	~30%	Pricing pressures, patent expiries

Investment “What-If” Scenarios

Scenario	Impact on Revenue	Key Assumptions	Likelihood
Patent Extention	+10% in 2026–2028	Successful patent litigation	High
Biosimilar Penetration	-20% post-2026	Entry of biosimilars into primary markets	Moderate
Label Expansion Success	+15% in 2024–2025	Approvals for alopecia, additional autoimmune indications	High

---

Comparison with Leading Competitors

Attribute	XELJANZ	Humira (AbbVie)	Rinvoq (BMS)	Olumiant (Lilly)
Mechanism	JAK1/3 inhibitor	Anti-TNF biologic	JAK1 inhibitor	JAK1/2 inhibitor
Oral versus Injectable	Oral	Injectable	Oral	Oral
Market Penetration	Established, stable	Market leader, biosimilar threat	Growing with expanding indications	Emerging, competitive
Safety Profile	Concerns over infections, blood clots	Well-established, but side effects exist	Similar concerns	Similar concerns
Revenue (2022)	~$1.95 billion	~$20 billion	~$2 billion	~$469 million

Source: IQVIA, Pfizer Reports, BMS, Lilly presentations.

---

Deep Dive: Regulatory and IP Barriers

Regulatory Trends

• Increased post-market surveillance.
• Potential risk management mitigations affecting prescribing behavior.
• US FDA’s REMS programs for JAK inhibitors may influence uptake.

Patents and Exclusivity

Patent Type	Expected Expiry	Strategic Actions
Composition Patent	2026	Patent extensions, new indications
Method-of-Use Patents	2028–2030	Patent strategy, expanding approved uses
Data Exclusivity	2026–2031	Regulatory delay for biosilars

---

FAQs

1. What factors influence the future valuation of XELJANZ?

Key factors include patent expiration timelines, regulatory approval of new indications, safety profile developments, biosimilar competition, and pricing policies.

2. How does safety concern impact XELJANZ's market potential?

Safety issues, especially regarding infections, blood clots, and cardiovascular risk, can restrict usage in certain populations, leading to revenue mitigation. Enhanced safety profiles through next-generation formulations could offset this impact.

3. What are the primary competitors to XELJANZ?

Humira (AbbVie), Rinvoq (BMS), and Olumiant (Lilly) are principal competitors. Biosimilars of biologics threaten market share, while newer oral agents challenge XELJANZ's positioning.

4. What is the significance of patent expiries for XELJANZ?

Patent expiries around 2026 open pathways for biosimilar competition, risking revenue erosion. Patent extensions and new indications are strategic responses.

5. What markets offer the most growth opportunities for XELJANZ?

Ulcerative colitis (UC) and other autoimmune diseases (psoriatic arthritis, alopecia areata) present significant growth potential, driven by increased approvals and unmet medical needs.

---

Key Takeaways

• Steady Revenue Growth: XELJANZ has experienced consistent annual growth (~7%) driven by expanding indications and market penetration.
• Patent and Competition Risks: Patent expiry in 2026 could induce biosimilar competition, challenging future revenues, necessitating strategic patent management.
• Pipeline and Indication Expansion: Ongoing clinical trials and label expansion for UC, alopecia areata, and psoriasis are critical to sustaining growth.
• Regulatory Environment: Increased safety scrutiny and potential restrictions may impact sales, though Pfizer’s proactive regulatory engagement buffers risks.
• Market Opportunities: The autoimmune segment, especially UC, remains promising, with projected revenues reaching ~$2.2 billion globally by 2025.

Investors should weigh the compound effects of patent cliffs, safety concerns, and pipeline progress in assessing XELJANZ’s full investment potential within the evolving autoimmune therapeutics landscape.

---

References

[1] Pfizer Annual Reports (2020-2022)
[2] IQVIA MIDAS Data, 2022
[3] FDA and EMA approvals, public records
[4] Industry analysis reports, 2022
[5] Patent filings, USPTO, 2022